An investigator initiated prospective single arm open-label study to evaluate effectiveness of Camylofin 50 mg and Paracetamol 325mg inpatients with acute colicky abdominal pain - ACAP Study

Abbott Healthcare Pvt Ltd0 个研究点目标入组 0 人开始时间: 待定最近更新: 2024年8月19日

试验速览

暂无简介。

•Female subjects aged 18 65 years
•Patients attending OPD with acute colicky abdominal pain and having at least one episode of colicky pain within 24 hours prior to the visit
•Non complicated cases of acute colicky abdominal pain may be confirmed by imaging tests such as Ultrasound Sonography USG performed prior to the treatment initiation to ensure no
•complicated cases get recruited as perwill be performed at the discretion of the investigator
•Patient willing to provide written informed consent to will be enrolled in the study

•Patients with history of hypersensitivity to the study drugs any of study drugs ingredients
•Patients who had undergone coronary artery bypass graft surgery with epilepsy or inflammatory bowel disease will be excluded
•Patients with chronic abdominal pain such as Celiac disease lactose intolerance ulcerative colitis and Crohns disease
•Patients who may have narrow angle glaucoma mechanical stenosis Pregnancy and lactation Urinary retention Mega colon GI
•hemorrhage Tachyarrhythmia Porphyria
•Patients with any other conditions or diseases that investigator considers as ineligible to enroll in the study based on approved
•prescribing information

发起方